VISION

Inspiring transformational change in the

field of oncology diagnostics

MISSION

To develop and deliver accurate, rapid, minimally

invasive oncology diagnostic products utilising our

patented MCM5 antibodies

Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.

ADXBLADDER

MCM5 ELISA KIT


MCM Technology

 


Latest News

Arquer Diagnostics @Arquer Diagnostics
Recent #medicalstudies have highlighted a need for more research into #mentalhealth interventions for #patients #diagnosed with #urological #cancer, who are at an increased risk. Read more: https://t.co/5oflWPOCA3 https://t.co/CXLa3fVb49

- 17 days ago

1 1
Arquer Diagnostics @Arquer Diagnostics
The #clinical #research behind #ADXBLADDER is now described in the #EuropeanUrologyOncology Journal. Find out how effectively ADXBLADDER diagnoses bladder cancer here: https://t.co/ZiQRDmpBoM https://t.co/aLBewnK4qP

- 26 days ago

4 6
Arquer Diagnostics @Arquer Diagnostics
Protect your skin from the #Summer Sun and use #SPF 30 or higher to prevent #skin #cancer. Enjoy the Sun, safely! #Arquer #ArquerDiagnostics #health #diagnostics #sunsafety https://t.co/ZenWXfwM7U

- 30 days ago

Arquer Diagnostics @Arquer Diagnostics
#Innovation at #Arquer fuels our passion for #diagnostics. Our #ADXBLADDER is highly effective at detecting #cancer cells, so rapid and effective treatment can be given to patients early on. Let's #beatcancer together! https://t.co/kUTjbMEwVh https://t.co/uAx3qoctKI

- 36 days ago

1
Arquer Diagnostics @Arquer Diagnostics
Our #ADXBLADDER test allows #urologists to successfully monitor the recurrence of #bladder #cancer more effectively. Find out more: https://t.co/FhOvCtBxtO https://t.co/p3GvWoH3H1

- 45 days ago

2 2